To include your compound in the COVID-19 Resource Center, submit it here.

VX-148: Phase II

Interim analysis of a 12-week Phase II trial showed that VX-148 was generally well-tolerated

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE